Daniels Jo, Pauling John D, Eccleston Christopher
Department of Psychology, The University of Bath, Bath, UK.
Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UK.
BMJ Open. 2018 Dec 14;8(12):e024528. doi: 10.1136/bmjopen-2018-024528.
Raynaud's phenomenon (RP) is a significant cause of morbidity. Vasodilator medications cause unwanted adverse effects, with behavioural and lifestyle changes forming the mainstay of self-management; this is difficult to implement successfully. The objectives of this study were to evaluate the efficacy of behaviour change interventions for RP and identify learning points for future treatment development.
Systematic literature review and narrative synthesis of findings.
EMBASE, MEDLINE, Cochrane and PsycINFO were searched for eligible studies on 22 August 2017.
Randomised controlled trials (RCTs) of behaviour change interventions with at least one control comparator arm.
Study selection, data extraction and risk of bias were assessed independently by two reviewers, reaching consensus with a third when necessary. Primary outcomes of interest included severity/impact, frequency and duration of RP episodes, pain, disability, adverse events and study withdrawal.
Of 638 articles retrieved, eight studies fulfilled criteria for inclusion. Biofeedback was the active behaviour change treatment arm for seven studies, with one study reporting a behavioural intervention. Studies were published 1978-2002; six were USA-based studies, one German and one Swedish. Using Cochrane Risk of Bias assessment, studies were assessed to be overall at high risk of bias, with the exception of one large RCT. The total sample included 495 participants (study median=29), with a median age of 39.5 years and preponderance towards females (73%). Five studies reported significant effects in primary outcomes of interest; however, due to missing data, relative efficacy of interventions could not be reliably assessed.
There is no evidence to support or refute claims of the efficacy of behaviour change interventions for the management of RP. There remains a strong case for developing and testing behaviour change interventions that focus on self-management; however, theoretical development and advancement in trial quality is imperative to underpin future work.
CRD42017049643.
雷诺现象(RP)是导致发病的一个重要原因。血管扩张剂药物会产生不良副作用,行为和生活方式的改变是自我管理的主要方式,但这很难成功实施。本研究的目的是评估行为改变干预对RP的疗效,并确定未来治疗发展的经验教训。
系统文献综述和研究结果的叙述性综合分析。
2017年8月22日检索了EMBASE、MEDLINE、Cochrane和PsycINFO以查找符合条件的研究。
具有至少一个对照比较组的行为改变干预的随机对照试验(RCT)。
由两名评审员独立评估研究选择、数据提取和偏倚风险,必要时与第三名评审员达成共识。感兴趣的主要结局包括RP发作的严重程度/影响、频率和持续时间、疼痛、残疾、不良事件和研究退出情况。
在检索到的638篇文章中,有8项研究符合纳入标准。生物反馈是7项研究中的积极行为改变治疗组,有1项研究报告了行为干预。研究发表于1978年至2002年;6项是美国的研究,1项德国研究和1项瑞典研究。使用Cochrane偏倚风险评估,除一项大型RCT外,研究总体被评估为具有较高的偏倚风险。总样本包括495名参与者(研究中位数=29),中位年龄为39.5岁,女性占多数(73%)。5项研究报告了在感兴趣的主要结局方面有显著效果;然而,由于数据缺失,无法可靠评估干预措施的相对疗效。
没有证据支持或反驳行为改变干预对RP管理疗效的说法。仍然有充分的理由开展和测试侧重于自我管理的行为改变干预措施;然而,理论发展和试验质量的提高对于支持未来的工作至关重要。
PROSPERO注册号:CRD42017049643。